IMMUNOTHERAPY Benefit with anti-PD-L1

被引：1
|
作者：
Romero, Diana
机构：
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2017年 / 14卷 / 02期
关键词：
D O I：
10.1038/nrclinonc.2016.218
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [41] Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
    Puccini, Alberto
    Battaglin, Francesca
    Iaia, Maria Laura
    Lenz, Heinz-Josef
    Salem, Mohamed E.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [42] New insights into the anti-PD-L1 and anti-PD-1 reagents in cancer therapy
    Chen, Cheng
    Huang, Jian-An
    EUROPEAN JOURNAL OF INFLAMMATION, 2016, 14 (01) : 61 - 65
  • [43] Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models
    Wang, Sarah
    Sun, Kaiming
    Xiao, Yonghong
    Feng, Bin
    Mikule, Keith
    Ramaswamy, Sridhar
    Hanke, Jeffrey
    Wang, Jing
    CANCER RESEARCH, 2018, 78 (13)
  • [44] Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
    Swaika, Abhisek
    Hammond, William A.
    Joseph, Richard W.
    MOLECULAR IMMUNOLOGY, 2015, 67 (02) : 4 - 17
  • [45] Pulmonary Sarcoidosis Associated With Anti-Pd-L1 Therapy
    Balestra, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [46] Anti-PD-L1 therapy: patient selection is important
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2016, 13 (3) : 134 - 134
  • [47] Product review on the Anti-PD-L1 antibody atezolizumab
    Shah, Neil J.
    Kelly, William J.
    Liu, Stephen V.
    Choquette, Karin
    Spira, Alexander
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (02) : 269 - 276
  • [48] Anti-PD-L1 peptide improves survival in sepsis
    Shindo, Yuichiro
    McDonough, Jacquelyn S.
    Chang, Katherine C.
    Ramachandra, Murali
    Sasikumar, Pottayil G.
    Hotchkiss, Richard S.
    JOURNAL OF SURGICAL RESEARCH, 2017, 208 : 33 - 39
  • [49] Anti-PD-L1 inhibitor durvalumab in bladder cancer
    Brower, Vicki
    LANCET ONCOLOGY, 2016, 17 (07): : E275 - E275
  • [50] Product review: avelumab, an anti-PD-L1 antibody
    Collins, Julie M.
    Gulley, James L.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 891 - 908
12345